Pharmacological add-on therapies showed no significant efficacy beyond corticosteroids but may improve quality of life, and risk of bias ranged from moderate to high, with low statistical heterogeneity.
Abstract
Cutaneous sarcoidosis is a granulomatous skin disease associated with significant quality-of-life impairment. Evidence from randomized controlled trials (RCTs) guiding systemic or targeted therapy remains limited. To assess the efficacy and safety of pharmacological therapies for cutaneous sarcoidosis in randomized placebo-controlled trials PubMed, the Cochrane Library and ClinicalTrials.gov were searched through January 2025. Eligible studies were RCTs including adults with cutaneous sarcoidosis randomized to pharmacological therapy vs placebo. Outcomes were clinical response, quality of life and serious adverse events. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random-effects models. Six RCTs including 156 participants were analysed. Pharmacological therapies did not significantly improve clinical response compared with placebo (OR 2.24; 95% CI, 0.73–6.90; p=0.16). A nonsignificant trend toward improved quality of life was observed (OR 2.23; 95% CI, 0.87–5.73; p=0.09). No significant difference in serious adverse events was found between groups (OR 0.97; 95% CI, 0.48–1.96; p=0.93). Risk of bias ranged from moderate to high, with low statistical heterogeneity. Pharmacological add-on therapies showed no significant efficacy beyond corticosteroids but may improve quality of life. Larger, well-designed RCTs are needed.
A common chronic skin condition that affects a good number of people worldwide, psoriasis frequently coexists with psoriatic arthritis. The strain this illness places on healthcare systems is substantial. This systematic review and meta-analysis evaluated the efficacy and safety of systemic biological and non-biologica...
Sultan Jafaari, O. Mobarki, Dania Sulia et al.· International Journal of Med...· 0 citations
Background Systemic targeted therapies are reshaping treatment for prurigo nodularis (PN), but the timing of clinically meaningful benefits and the strength of supporting evidence remain unclear. We synthesized direct placebo-controlled evidence by outcome and follow-up time, distinguishing replicated phase 3 evidence...
Yue Yu, Si-Qi Li, Wei-Wen Chen et al.· Frontiers in Medicine· 0 citations
BACKGROUND
Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease characterized by esophageal dysfunction and eosinophilic inflammation. Comparative efficacy and safety of therapies remain uncertain.
OBJECTIVE
To compare efficacy and safety of treatments for EoE in children and adults.
METHODS
We condu...
Y. Roldan, I. Silang, D. Rayner et al.· Journal of Allergy and Clini...· 0 citations
Crohn's disease and ulcerative colitis are chronic inflammatory bowel diseases (IBDs) driven by the interleukin-23/Th17 pathway. Guselkumab, a selective interleukin-23p19 monoclonal antibody, has shown promise in phase II/III trials. This systematic review and meta-analysis aimed to synthesize its efficacy and safety v...
Z. Shahid, M. Azam, Ahila Ali et al.· European Journal of Gastroen...· 0 citations
Objective To compare the effectiveness of drug treatments for the management of fibromyalgia. Design Systematic review and network meta-analysis of randomised trials. Data sources Medline, Embase, AMED (Allied and Complementary Medicine Database), PsycInfo, CINAHL, and Cochrane CENTRAL (Cochrane Central Register of Con...
Dena Zeraatkar, J. P. Lima, S. Kirsh et al.· BMJ Medicine· 0 citations